SMS Pharmaceuticals Limited – Investor Presentation Summary
Key Operational Highlights
- Revenue increased 6% YoY driven by diversified growth across high-value APIs.
- Gross margin remained above 45%, reflecting structural improvement in unit economics.
- Completed 4 DMF/CEP filings in Q1FY27; on track to meet FY27 target of 10 DMF/CEP filings.
- R&D team strength increased to 200 scientists, supporting development pipeline of niche and high-value APIs and peptides.
- Reactor volume stands at 3,120 KL.
- The company has a presence in 75+ countries with 800+ customers.
Key drivers of operational performance:
Diversified API portfolio across therapeutic areas, strong foothold in regulated markets (88% of revenue), scalable manufacturing enabling operating leverage, and strategic R&D focus driving process optimization.
Segment-wise Performance
- Anti-inflammatory: 20% of FY26 revenue (High-volume category)
- Anti Retro Viral (ARV): 28% of FY26 revenue (High-volume category)
- Anti-diabetic: 15% of FY26 revenue (High-value category)
- Anti-migraine: 11% of FY26 revenue (High-value category)
- Anti-ulcer: 5% of FY26 revenue (High-volume category)
- Anti-erectile dysfunction: 6% of FY26 revenue (High-value category)
- Anti-epileptic: 6% of FY26 revenue (High-value category)
- Anti-anginal: 5% of FY26 revenue (High-value category)
- Others: 4% of FY26 revenue (High-value category)
Explanation of significant changes in segment performance:
Not Specified
Financial Highlights
- Revenue: ₹207.9 crore (Q1FY27)
- Gross Profit: ₹74.93 crore (Q1FY27)
- Gross Margin: 36% (Q1FY27)
- EBITDA: ₹40.95 crore (Q1FY27)
- EBITDA Margin: 20% (Q1FY27)
- PAT: ₹20.20 crore (Q1FY27, excludes share of profit/(loss) from associate)
- PAT Margin: 10% (Q1FY27)
- EPS: ₹2.23 (Q1FY27)
YoY/QoQ comparison:
- Revenue: Up 6% YoY
- Gross Profit: Up 12% YoY
- EBITDA: Up 4% YoY
- PAT: Up 8% YoY (excluding associate contribution)
Drivers of financial performance:
Higher revenue growth, diversified product portfolio, and operational efficiencies.
Comparison to market estimates:
Not Specified
Key Risks:
Not Specified
Geographical Revenue Split
- Domestic vs Export/Regional Revenue: Not Specified
- Regional Breakdown: Not Specified
Balance Sheet Snapshot
- Net Debt/Equity: Not Specified
- Reserves: Not Specified
- Current Assets/Liabilities: Not Specified
- Working Capital/Leverage Metrics: Not Specified
Financial Health Insights:
Stable majority share of high-value product portfolio and OCF conversion on par with leading API companies.
Capex & Cash Flow Health
- Capital Expenditure: ₹280 crore capex programme progressing as planned; expected to be completed by FY27.
- Free Cash Flow: Not Specified
- Operating Cash Flow: Not Specified
- Net Debt Movement: Not Specified
Investment Rationale:
Focus on capacity expansion, technology upgrades, and backward integration projects to improve margins.
Strategic & R&D Initiatives
- Investments in Innovation: Targeting 20 DMF, CEP and dossier filings over next 24 months; R&D investment to double over next 15 months.
- Product pipeline includes lab scale development and commercial validation completed for Anti-inflammatory, Anti-diabetic, Anti-depressant, Anti-hypertensive, Antipsychotic, and Ulcerative colitis APIs.
- Board approved infusion of up to ₹50 crore as loan into subsidiary SMS Peptides Private Limited to build on its dedicated peptide R&D facility.
Expected impact on growth:
Not Specified
Strategic Rationale:
Expanding into high-value molecules and peptides, reducing operational costs through backward integration, and strengthening product portfolio.
Industry Trends & Business Environment
- Macro/Industry Trends: Not Specified
- Impact on Company: Not Specified
Management Commentary & Growth Outlook
- Strategic Outlook: Focused strategy in place to deliver revenue growth with margin expansion; targeting 1.75 average net asset turnover levels over next 2-3 years (from current 1.36).
- FY Guidance: Target of 10 DMF/CEP filings for FY27.
- Market Share Targets: Targeting to become #1 player in the world for Anti-inflammatory APIs; aiming for market share wins in key APIs.
Risks and Opportunities:
Not Specified